Список проголосовавших за комментарий " On The Wires<ul><li>Angsana Molecular & Diagnostics has announced that it will be a partner molecular test laboratory for STARTRK-2 clinical trial sites in Asia working with Ignyta, (<strong>RXDX</strong>), a biotechnology company focused on precision medicine in oncology. Angsana Molecular & Diagnostics' RNA-based fusions cancer panel will be used for screening TRK, ROS1 and ALK fusions in the STARTRK-2 clinical trial, a registration-enabling global Phase 2 basket clinical trial for entrectinib, Ignyta's investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions.</li><li>On March 2, 2017, The Bank of Nova Scotia (<strong>BNS</strong>) entered into a private agreement with an arm's length third party seller to purchase for cancellation 1,000,000 of the Bank's common shares held by such seller for an aggregate purchase price of CAD$70,840,000.</li><li>Trans World Entertainment Corporation (<strong>TWMC</strong>) Founder, Chairman and former CEO Robert J. (Bob) Higgins died on March 1st, 2017. He was 75 years old. Trans World CEO Mike Feurer stated, «All of us at Trans World were deeply saddened by the passing of our Founder Bob Higgins. Serving as its relentless champion, Bob was very proud of Trans World Entertainment and all of its Associates. His never-ending drive to excellence, determination, and commitment to our Company is the standard that will inspire and stay with us as we honor the legacy he created over the last 45 years. On behalf of our Board of Directors, Management team and all of our Associates across the country, we mark Bob's passing, mourn his loss, celebrate his renown and extend our deepest sympathies to his wife, Anne, and the entire Higgins family.»</li></ul>"